PO Box 4214
Morgantown, West Virginia 26504
Phone 681-212-9255

Our Focus

The West Virginia Chapter of the National Hemophilia Foundation, WVNHF, provides education, support, awareness, and advocacy for the bleeding disorder community. 

We are the leading resource for West Virginians affected by bleeding disorders. You can count on us to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.

News Articles

NHF's Wednesday Webinars for March 2021 will feature an array of speakers and topics of interest to both healthcare providers and patients and families with blood disorders alike.

March Webinars
All webinars are from 2:00pm-3:00pm ET.

 

March 3, 2021

Cellular Therapies for Hemophilia 

Speakers: Amy Shapiro, MD, Indiana Hemophilia & Thrombosis Center, Inc. and Deya Corzo, MD, Sigilon Therapeutics

 

The U.S. Food and Drug Administration (FDA) has partially rescinded a pair of supplemental Biologics License Applications (BLAs) the agency had granted, in error, for two recombinant factor IX products, BeneFIX® (Pfizer) and IXINITY (Aptevo). The supplemental BLAs in question were both approved by the FDA in 2020 and represented additional indications that ultimately ran against exclusivity rights of another product.   

Background:

Fitusiran is an RNA drug that can prevent antithrombin protein from being made in the liver. Antithrombin is an important brake for the coagulation system. Insufficient amounts of circulating antithrombin in normal adults lead to thrombosis. In persons with hemophilia (PWH) A or B, who don’t have sufficient clotting, lowering antithrombin with fitusiran has been shown to increase coagulation and protect PWH from bleeding. It is presently in Phase 3 clinical trials.


Advertisement

PO Box 4214
Morgantown, West Virginia 26504
Phone 681-212-9255

© West Virginia Chapter National Hemophilia Foundation 2021

Powered by Firespring